Recently, single drug therapy with an active antipseudomonal beta-lactam (eg, ceftazidime) or a fluoroquinolone has been shown to produce outcomes equivalent to those of previously recommended combination therapy with an aminoglycoside plus an antipseudomonal beta-lactam, an antipseudomonal cephalosporin (eg, ceftazidime, cefepime, cefoperazone), a monobactam (eg, aztreonam), or a carbapenem (meropenem, imipenem, doripenem).